La cadena de opciones muestra datos clave de las opciones de acciones de Coeptis Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Coeptis Therapeutics..

Coeptis Therapeutics (NASDAQ:COEP) Bolsa, Cadena de Opciones

Coeptis Therapeutics

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Movers

Trading Ideas

ARKR

AURA

BLRX

CHEK

CMCT

COEP

IDAI

LINC

MGOL

NINE

RSVR

Conoce las acciones que lideran el premercado tras movimientos clave: Check-Cap sube un 52,2% gracias a nueva patente.

Las acciones de Check-Cap suben un 52%; 20 acciones que se están moviendo antes de la apertura del mercado

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc. - Warrants

With this transition, Avanos will manage all sales, support, and distribution directly, reinforcing its dedication to delivering high-quality enteral feeding solutions.
For the past 29 years, Vygon UK, a supplier of surgical and medical devices has been a valued distributor of the MIC&#x2A; and MIC-KEY family of products.

News

AVNS

Avanos Medical Plans To Take Direct Responsibility For Sales And Distribution Of Its MIC-KEY Enteral Feeding Products In UK, Effective July 25, 2025

Norwegian Cruise Line Holdings &nbsp;and NCL Corporation Ltd., a subsidiary of the Company ("NCLC"), announce that NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the "Holders") of NCLC's 5.375% Exchangeable Senior Notes due 2025 (the "2025 Notes"), pursuant to which NCLC and the Holders have agreed to exchange (the "Exchange") $285,425,000 in aggregate principal amount of the Holders' 2025 Notes for (i) $285,425,000 in aggregate principal amount of NCLC's newly issued 0.875% Exchangeable Senior Notes due 2030 (the "2030 Notes") and (ii) an aggregate cash payment (the "Cash Payment") of $51,624,820, plus accrued and unpaid interest on the 2025 Notes to be exchanged to, but excluding, the closing date of the Exchange. The Cash Payment will be equal to the proceeds from the concurrent Equity Offering, as described below, and represents the remainder of NCLC's exchange obligation in excess of the aggregate principal amount of the 2025 Notes to be exchanged.
Concurrently, the Company announces a registered direct offering of 2,708,533 ordinary shares to the Holders at a price of $19.06 per share (the "Equity Offering" and together with the Exchange, the "Transactions"). The Company expects to use the proceeds from the Equity Offering to make the Cash Payment.

NCLH

NCLH To Cut Fully Diluted Share Count By 12.5M Following Note Exchange And Equity Sale

Telsey Advisory Group analyst Dana Telsey maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Outperform and maintains $90 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on PVH, Maintains $90 Price Target

PROP

Prairie Operating Co. Launches 11-Well Development Program At Rusch Pad In Colorado's DJ Basin

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

Reiteration

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

CRGO

Freightos Expands With Air Europa Partnership, Enhancing Digital Freight Booking Across Spain-Latin America Routes

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $23 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $23 Price Target

Financial Outlook
BlackBerry is providing the following guidance for the first fiscal quarter and the full fiscal year 2026 (ending February 28, 2026).
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Q1 FY26</td>
<td>Full fiscal year FY26</td>
</tr>
<tr>
<td>Total BlackBerry revenue:</td>
<td>$107 - $115 million</td>
<td>$504 - $534 million</td>
</tr>
<tr>
<td>QNX revenue:</td>
<td>$51 - $55 million</td>
<td>$250 - $270 million</td>
</tr>
<tr>
<td>Secure Communications revenue:</td>
<td>$50 - $54 million</td>
<td>$230 - $240 million</td>
</tr>
<tr>
<td>Licensing revenue:</td>
<td>Approximately $6 million</td>
<td>Approximately $24 million</td>
</tr>
<tr>
<td>QNX segment adjusted EBITDA:</td>
<td>$2 - $6 million</td>
<td>$55 - $60 million</td>
</tr>
<tr>
<td>Secure Communications segment</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>adjusted EBITDA:</td>
<td>$3 - $6 million</td>
<td>$34 - $44 million</td>
</tr>
<tr>
<td>Licensing segment adjusted EBITDA:</td>
<td>Approximately $5 million</td>
<td>Approximately $20 million</td>
</tr>
<tr>
<td>Adjusted Corporate Costs:</td>
<td>Approximately $10 million</td>
<td>Approximately $40 million</td>
</tr>
<tr>
<td>Total Company adjusted EBITDA:</td>
<td>Breakeven - $7 million</td>
<td>$69 - $84 million</td>
</tr>
<tr>
<td>Non-GAAP basic EPS:</td>
<td>($0.01) - Breakeven</td>
<td>$0.08 - $0.10</td>
</tr>
<tr>
<td>Operating cash flow (usage)</td>
<td>($20) - ($30) million</td>
<td>Approximately $35 million</td>
</tr>
</tbody>
</table>
</figure>

Guidance

BlackBerry Now Expects FY26 Total Revenue Of $504M-$534M Vs $546.34M Est, Adj EPS Of $0.08-$0.10 Vs $0.10 Est

HC Wainwright &amp; Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Buy and raises the price target from $30 to $42.

MLYS

HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $42

Telsey Advisory Group analyst Dana Telsey maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Market Perform and maintains $15 price target.

Telsey Advisory Group Maintains Market Perform on Macy's, Maintains $15 Price Target

As a result, the company expects first quarter 2025 Adjusted Profit Before Tax&nbsp;in a range of $92.3 to $97.3 million (Q1 2024: $67.7 million).
 &nbsp;

Marex Group Expects Q1 Revenues $449.3M - $464.3M, Est $421.573M; Adj EPS Of $0.88 - $0.93, Est $0.77

BRKR

Bruker Announces Introduction Of d-DNP Polarizer For MRI Research And For Dynamic Nuclear Polarization Liquids NMR

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) with a Buy and maintains $32 price target.

SRZN

HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $32 Price Target

Republic National Distribution Company opens new distribution channels in six states including California, one of the largest markets in the U.S.

Innovation Beverage Group Expands U.S. Reach With Republic National Distribution Company Distribution Deal

Ziff Davis Acquires theSkimm And Maxroll In Q1 To Expand Global Reach And Product Portfolio

HC Wainwright &amp; Co. analyst Mitchell Kapoor upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintains the price target from $75 to $75.

Upgrades

SRPT

HC Wainwright & Co. Upgrades Sarepta Therapeutics to Neutral, Maintains Price Target to $75

BlackBerry Expects Q1 Total Revenue Of $107M-$115M Vs $127.99M Est, Adj EPS Of $(0.01)-Breakeven Vs $0.01 Est

DASH

Domino's Partners With DoorDash For Nationwide U.S. Launch In May 2025, Expanding To Canada Later

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and maintains $1.5 price target.

D. Boral Capital Maintains Buy on PEDEVCO, Maintains $1.5 Price Target

Renews highly coveted and valuable hockey rights long term Will deliver more national games and fewer blackouts to hockey fans Rogers is proud to remain the home of NHL&nbsp;hockey

NHL And Rogers Extend National Media Rights Partnership With 12-Year, $11B Agreement

Press Releases

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Biotech

General

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Health Care

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation

ALNY

AMZN

AVGO

BURU

GOOGL

MSFT

NVDA

REGN

RPRX

SMMT

VRTX

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

OSR Holdings

OS Therapies

Passage Bio

Pluri

Rallybio

RenovoRx

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Comments

Coeptis Therapeutics

Coeptis Therapeutics (COEP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL